United States

Profile: Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

23 Aug 2019
Change (% chg)

$-0.12 (-5.22%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Inovio Pharmaceuticals, Inc. (Inovio), incorporated on June 15, 2001, is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generate immune responses, in particular T cells, in the body to fight target diseases. The Company has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio's immunotherapies consist of one or more DNA plasmids encoding one or more selected antigens. Inovio's immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Cancer Vaccines/Immunotherapies

Inovio's VGX-3100 is an immunotherapy designed to manage immune responses (humoral and cell mediated) against the E6 and E7 antigens of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by the HPV types. The Company has completed the Phase II clinical trial for its VGX-3100. The Company's candidate, INO-3112 (VGX-3100 in combination with a DNA-based Interleukin 12 (IL-12) cytokine (INO-9012)), has completed Phase I/IIa clinical study stage for the treatment of head and neck cancer, and cervical cancer. The Company is in Phase I clinical study for INO-3106 alone or in combination with DNA-based IL-12 in subjects with HPV-6 associated invasive aerodigestive malignancies. The Company is in Phase I clinical trial for its human telomerase reverse transcriptase (hTERT) DNA immunotherapy (INO-1400) alone or in combination with its IL-12 immune activator (INO-9012) in adults with breast, lung and pancreatic cancers. It has completed pre-clinical study for INO-5400 (in combination with human telomerase reverse transcriptase (hTERT) and two antigens). It is also in Phase I clinical trial for INO-5150 in combination with DNA-based IL-12 cytokine.

Infectious Disease Vaccines/Immunotherapies

The Company's INO-8000/VGX-6150 for HCV is in the Phase I clinical trial stage. The Company is in clinical trial for INO-1800; INO-1800 in combination with DNA-based IL-28 cytokine; PENNVAX-GP; INO-4212, and GLS-5300. It completed Phase I clinical trials for INO-3510, and is in pre-clinical study for GLS-5700 and Biodefense targets. The Company's VGX-3400X candidate targets Highly Pathogenic Asian Avian Influenza A (H5N1). The immunotherapy consists of three DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences, and a nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1.

Synthetic DNA-based Monoclonal Antibodies (mAb) Products

The Company's DNA-based mAb targeting Chikungunya virus (CHIKV) is in the preclinical study stage of development. Its Synthetic Monoclonal Antibodies dMAb have an ability to alert the immune system to attack and kill specific cancer cells (as in the case of Yervoy) or block certain biochemical pathways (such as those leading to rheumatoid arthritis, as in the case of Remicade).

Electroporation Delivery Technology

Inovio's CELLECTRA Electroporation Systems has various configurations. Its first configuration covers intramuscular (IM) delivery of DNA and intradermal/subcutaneous delivery (ID) of DNA. Its CELLECTRA-5PSP device has been designed and developed to support its VGX-3100 Phase III study.

The Company competes with J&J, Sanofi, Aventis, GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Advaxis and Kite.

Company Address

Inovio Pharmaceuticals Inc

6769 Mesa Ridge Rd
SAN DIEGO   CA   92121-2995
P: +1858.4103134
F: +1858.4041392

Company Web Links